Urinary lithogenic risk profile in ADPKD patients treated with Tolvaptan

被引：0
|
作者：
Bargagli, Matteo [1 ]
Dhayat, Nasser [2 ]
Anderegg, Manuel [2 ]
Semmo, Mariam [2 ]
Huynh-Do, Uyen [2 ]
Vogt, Bruno [2 ]
Ferraro, Pietro Manuel [1 ]
Fuster, Daniel [2 ]
机构：
[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, UOC Nefrol, Rome, Italy
[2] Univ Bern, Bern Univ Hosp, Inselspital, Div Nephrol & Hypertens, Bern, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2019年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P 36
引用
收藏
页码：26S / 26S
页数：1
相关论文
共 50 条
  • [1] URINARY LITHOGENIC RISK PROFILE IN ADPKD PATIENTS TREATED WITH TOLVAPTAN
    Bargagli, Matteo
    Dhayat, Nasser A.
    Anderegg, Manuel
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel Guido
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 12 - 12
  • [2] Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
    Bargagli, Matteo
    Dhayat, Nasser A.
    Anderegg, Manuel
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (07): : 1007 - 1014
  • [3] Altered lipid metabolism in ADPKD patients treated with Tolvaptan
    Bargagli, Matteo
    Anderegg, Manuel
    Huynh-Do, Uyen
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel
    SWISS MEDICAL WEEKLY, 2022, 152 : 16S - 16S
  • [4] ADPKD, Tolvaptan, and Nephrolithiasis Risk
    Hoorn, Ewout J.
    Zietse, Robert
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (07): : 923 - 925
  • [5] Plasma markers of mineral metabolism in ADPKD patients treated with tolvaptan
    Bargagli, Matteo
    Dhayat, Nasser A.
    Anderegg, Manuel
    Semmo, Mariam
    Uyen Huynh-Do
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    SWISS MEDICAL WEEKLY, 2020, : 22S - 22S
  • [6] Plasma Biomarkers of Mineral and Bone Disorder in ADPKD Patients Treated with Tolvaptan
    Bargagli, Matteo
    Dhayat, Nasser
    Anderegg, Manuel
    Huynh-do, Uyen
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 205 - 205
  • [7] Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD
    Makabe, Shiho
    Manabe, Shun
    Kataoka, Hiroshi
    Akihisa, Taro
    Yoshida, Rie
    Ushio, Yusuke
    Sato, Masayo
    Tsuchiya, Ken
    Mochizuki, Toshio
    Nitta, Kosaku
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (09): : 2436 - 2444
  • [8] Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD
    Oporto, F. J. Roca
    Gomez, C. Andrades
    Cosano, G. Montilla
    Aguilera, A. Luna
    Rocha, Jose L.
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (04): : 1031 - 1039
  • [9] Urinary lithogenic profile and gut and urinary microbiota in patients with inflammatory bowel diseases
    Mignini, I.
    Masucci, L.
    De Maio, F.
    Laterza, L.
    Scaldaferri, F.
    Settanni, C. R.
    Napolitano, D.
    Baroni, S.
    Garcovich, M.
    Riccardi, L.
    Gasbarrini, A.
    Ferraro, P. M.
    Papa, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I405 - I406
  • [10] BOTH HYDROCHLOROTHIAZIDE AND METFORMIN AMELIORATE AQUARETIC SIDE-EFFECTS IN ADPKD PATIENTS THAT ARE TREATED WITH TOLVAPTAN
    Kramers, Bart
    Koorevaar, Iris
    Aapkes, Sophie
    Dekkers, Claire
    Heerspink, Hiddo Lambers
    Gansevoort, Ronald
    Meijer, Esther
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1 - 1
12345